Wockhardt Ltd Rs 1750
Background & Turnaround Story
Wockhardt has been through one of the more dramatic rollercoasters in Indian pharma history. After being an R&D-heavy pharma innovator, it was severely hit in the past decade due to manufacturing lapses and FDA import bans — basically crippling its global ambitions. To survive, the company had to divest non-core assets and pare down its operations drastically. It’s burned through capital, with over $500 million invested in R&D over the years and nothing substantial to show—until now, possibly.
